Loading publications…
The last 5 uploaded publications
Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.
Zahra Sabahi, Nathan Papa, Wolfgang P. Fendler, Andrew Nguyen, Keith Wong, Narjess Ayati, Bao Ho, Jeffrey Chen, Thomas W. Cusick, Irene A. Burger, Megan Crumbaker, Gavin Marx, Shikha Sharma, Mark Frydenberg, Shahneen Sandhu, Ian D. Davis, Martin R. Stockler, Christopher J. Sweeney, Anthony M. Joshua, Louise Emmett (2025). Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5091.
Article62 days agoValidation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial
Andrei Gafita, Andrew Martin, Louise Emmett, Matthias Eiber, Amir Iravani, Wolfgang P. Fendler, James Buteau, Shahneen Sandhu, Arun Azad, Ken Herrmann, Martin R. Stockler, Ian D. Davis, Michael S. Hofman (2024). Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial. , DOI: https://doi.org/10.1016/j.euo.2024.03.009.
Article62 days agoNomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Andrei Gafita, Jérémie Calais, Tristan Grogan, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Anna Zeldin, Hendrik Rathke, Wesley R. Armstrong, Andrew Robertson, Pan Thin, Calogero D’Alessandria, Matthew B. Rettig, Ebrahim S. Delpassand, Uwe Haberkorn, David Elashoff, Ken Herrmann, Johannes Czernin, Michael S. Hofman, Wolfgang P. Fendler, Matthias Eiber (2021). Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. , 22(8), DOI: https://doi.org/10.1016/s1470-2045(21)00274-6.
Article62 days agoNomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Andrei Gafita, Jérémie Calais, Tristan Grogan, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Anna Zeldin, Hendrik Rathke, Wesley R. Armstrong, Andrew Robertson, Pan Thin, Calogero D’Alessandria, Matthew B. Rettig, Ebrahim S. Delpassand, Uwe Haberkorn, David Elashoff, Ken Herrmann, Johannes Czernin, Michael S. Hofman, Wolfgang P. Fendler, Matthias Eiber (2021). Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. , 22(8), DOI: https://doi.org/10.1016/s1470-2045(21)00274-6.
Article62 days agoDevelopment and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study
Andrei Gafita, Jérémie Calais, Tristan Grogan, Anna Zeldin, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Hendrik Rathke, Wesley R. Armstrong, Andrew Robertson, Pan Thin, Calogero D’Alessandria, Matthew B. Rettig, Ebrahim S. Delpassand, Uwe Haberkorn, David Elashoff, Ken Herrmann, Johannes Czernin, Prof Michael S. Hofman, Wolfgang P. Fendler, Matthias Eiber (2021). Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study. , DOI: https://doi.org/10.2139/ssrn.3798566.
Article62 days ago